GlassScriptPhysician profile
Jillian Lee Pattison
NPI 1528420783
$625.06
in general payments reported to CMS, 2019-2025
13 companies · $189 in 2025
The $189 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $55.66 · 2023: $350 · 2024: $30.42 · 2025: $189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $569.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $569.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $163.29 | 2025 | Twiist |
| Beta Bionics, INC. | $109.93 | 2023 | Ilet Bionic Pancreas |
| Insulet Corporation | $103.81 | 2023 | Omnipod |
| Lilly USA, LLC | $69.20 | 2022-2023 | Jardiance, Humulin, Mounjaro |
| Medtronic, INC. | $32.13 | 2023 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $26.17 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $21.52 | 2023 | |
| Dexcom, INC. | $20.44 | 2023 | Dexcom G6 Transmitter |
| Amryt Pharma Holdings LTD | $16.81 | 2022 | |
| Cequr Corporation | $16.08 | 2024 | Cequr Simplicity |
| Novo Nordisk INC | $15.87 | 2023 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $15.47 | 2022 | |
| Tandem Diabetes Care, INC. | $14.34 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jillian Pattison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.